Sort   by:  
 Page size 
GenomicsEGAD00000000052
Sequencing data from natching Pancreatic Carcinoma samples
EGAD00000000052 | EGA
GenomicsThe patterns and dynamics of genomic instability in metastatic pancreatic cancer
Pancreatic cancer is an aggressive malignancy with a five-year mortality of 97–98%, usually due to widespread metastatic disease. Previous studies indicate that this disease has a complex genomic landscape, with frequent copy number changes and point mutations, but genomic rearrangements have not ...
EGAS00000000064 | EGA
GenomicsEGAD00000000053
Sequencing data from Breast Cancer samples
EGAD00000000053 | EGA
GenomicsComplex Landscapes of Somatic Rearrangements in Human Breast Cancer Genomes
We have used massively parallel paired end sequencing strategies to reconstruct the genomic landscape of 24 breast cancer genomes, through the identification and characterization of 2166 somatically acquired genomic rearrangements. These studies have revealed considerable complexity in the patterns ...
EGAS00000000062 | EGA
GenomicsEGAD00000000054
NCI-H209 is an immortal cell line derived from a bone marrow metastasis of a patient with small cell lung cancer, taken before chemotherapy. The specimen showed histologically typical small cells with classic neuroendocrine features. NCI-BL209 is an EBV-transformed B-cell line derived from the same ...
EGAD00000000054 | EGA
GenomicsA small cell lung cancer genome reports complex tobacco exposure signatures
Cancer is driven by mutation. Worldwide, tobacco smoking is the major lifestyle exposure that causes cancer, exerting carcinogenicity through 60 chemicals that bind and mutate DNA. Using massively parallel sequencing technology, we sequenced a small cell lung cancer cell line, NCI-H209, to explore t...
EGAS00000000051 | EGA
MetabolomicsGeographic variation of mutagenic exposures in kidney cancer genomes

International differences in the incidence of many cancer types indicate the existence of carcinogen exposures that have not been identified by conventional epidemiology yet potentially make a substantial contribution to cancer burden1. This pertains to clear cell renal cell carcinoma (ccRCC), fo...

2024-03-26 | MTBLS9394 | MetaboLights
Sort   by:  
 Page size